Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.67 |
| ▸ | SYK | P43405 | 6/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15712569 | 0.98 | DHODH (0.67) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712220 | 0.96 | DHODH (0.72) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL30757588 | 0.96 | DHODH (0.72) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712636 | 0.91 | DHODH (0.56) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712269 | 0.90 | DHODH (0.65) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712566 | 0.90 | SYK (0.56) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712681 | 0.90 | DHODH (0.63) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL30757511 | 0.90 | DHODH (0.63) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712388 | 0.89 | DHODH (0.64) | DHODHSYKERBB2EGFRERBB4 | |
| SCHEMBL15712814 | 0.89 | DHODH (0.64) | DHODHSYKERBB2EGFRERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2915804-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014069510-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | HRH4, CLIC4, KRT18 | DHODH 1568/4885SYK 3515/4885ERBB2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.